Figure 1: Nasal anti-CD3 with Low and High Dose semaglutide promote Liver Homeostasis in DIO
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
30. Oktober 2024 08:30 ET | Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
MYAHV_FFN_Trimsulin-7
New Study Finds Trimsulin Achieves 243% Greater Weight Loss than Semaglutide without Serious Side Effects
24. Oktober 2024 08:30 ET | FirstFitness Nutrition
New Study Finds Trimsulin Achieves 243% Greater Weight Loss than Semaglutide without Side Effects Offering a Natural GLP-1 Alternatative for Weight Loss.
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
21. Oktober 2024 07:30 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
Sesame, America’s Lo
Sesame, America’s Low-Cost Leader in Healthcare, Is First Major Direct-to-Consumer Weight Loss Company to Offer Compounded Semaglutide to All 50 United States
16. Oktober 2024 08:05 ET | Sesame
NEW YORK CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced that it has begun offering...
800 px horizontal logo.png
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
03. Oktober 2024 15:45 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
High Use of Ozempic and Other Diabetes Drugs for Weight Loss Driving Down Clothing Sizes In New York City, According to New Study
17. Juni 2024 07:00 ET | Impact Analytics
Impact Analytics announced that size small has become the most popular size for women on Manhattan’s Upper East Side.
New Weight Loss Drugs Pose Anesthesia Risk, according to Journal of American Physicians and Surgeons
06. Juni 2024 13:02 ET | Association of American Physicians and Surgeons
Weight loss drugs such as semaglutide impede stomach emptying, creating a significant risk from anesthesia. The effect may last for up to two months
800 px horizontal logo.png
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01. Mai 2024 09:00 ET | Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Costco unveils new weight loss service with healthcare partner Sesame
Wholesale Weight Loss: Sesame Unveils Specialized Care for Weight Loss with Pricing Exclusively for Costco Members
02. April 2024 10:59 ET | Sesame
NEW YORK CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans,  today unveiled an...
CTLT Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Catalent, Inc. for Potential Securities Law Violations
07. Februar 2024 09:13 ET | Wohl & Fruchter LLP
MONSEY, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Catalent, Inc. (NYSE: CTLT) (“Catalent”) has violated federal securities laws based...